FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a method for producing genetically engineered T-cells for immunotherapy, and can be used in medicine.
EFFECT: method enables producing pathologically targeted T-cells for immunotherapy, which can be provided by chimeric antigenic receptors aimed at an antigen marker which is common for pathological cells and for said T cells, where the genes coding said markers are inactivated in said T cells and avoid self-elimination of the targeted T cells in immunotherapy.
42 cl, 17 dwg, 24 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 | 2015 |
|
RU2727451C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
| CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) FOR CANCER TREATMENT | 2019 |
|
RU2811466C2 |
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2014 |
|
RU2732236C2 |
| CELL | 2015 |
|
RU2768019C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| CENTRAL MEMORY T-CELLS FOR ADOPTIVE T-CELL THERAPY | 2015 |
|
RU2763523C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
